Influence of MAC combined enalapril on BNP, RDW levels in patients with chronic heart failure / 心血管康复医学杂志

ABSTRACT

Objective: To explore therapeutic effect of meglumine adenosine cyclophosphate (MAC) combined enalapril on patients with chronic heart failure (CHF).Methods: A total of 90 CHF patients treated in our hospital were selected and randomly divided into routine treatment group (n=45) and combined treatment group (n=45, received MAC combined enalapril therapy based on routine treatment).Plasma brain natriuretic peptide (BNP), red cell distribution width (RDW), left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac output (CO) and heart function improvement were compared between two groups before and after treatment.Results: After four-week treatment, compared with before treatment, there were significant improvements in all indexes in both groups after treatment, P<0.05 or <0.01.Compared with routine treatment group after treatment,there was sighificantly improvement in marked inprovement rate(22.2% vs.40.0%,P=0.004)in combined treatment group;there were significant reductions in levels of BNP [(489.8±268.4) pg/ml vs.(332.5±253.8) pg/ml], RDW [(14.01±2.34)% vs.(13.02±2.11)%] (P<0.05 or <0.01), and significant rise in LVEF [(43.6±8.2)% vs.(47.8±7.3)%], SV [(45.9±5.69)ml vs.(54.2±6.12)ml] and CO [(4.23±0.55)L/min vs.(4.80±0.54)L/min] in combined treatment group, P<0.05 or <0.01.Conclusion: MAC combined enalapril can significantly reduce levels of BNP and RDW, and possess significant therapeutic effect in patients with chronic heart failure.